The aim of this study is to evaluate the efficacy of alirocumab for in-stent neoatherosclerosis by using optical coherence tomography, in comparison with standard statin therapy.
The investigators investigate to evaluate the efficacy of alirocumab for in-stent neoatherosclerosis. The investigators enrolled the patient who performed drug eluting stent implantation and detected in-stent neoatherosclerosis by follow up optical coherence tomography, and categorized into two group; the patients with alirocumab and rosuvastatin the investigatorsre categorized alirocumab therapy group, and the patients with rosuvastatin alone were categorized standard statin therapy group. The investigators compare these two group for outcomes.
Study Type
OBSERVATIONAL
Enrollment
31
the administration of Alirocumab at least 75mg every 2 weeks
Kobe University Graduate School of Medicine, Department of Cardiology
Kobe, Hyōgo, Japan
RECRUITINGLipid index change between baseline and 9 month follow-up
Lipid core arc was measured by every 0.2-mm interval throughout segments with neoatherosclerosis (NA) on optical coherence tomography (OCT) findings. The mean lipid core arc was calculated for each lesion. Then, the lipid index was calculated by multiplying the mean lipid core arc by the lipid core longitudinal length.
Time frame: Baseline and 9 month follow-up
Macrophage grade change between baseline and 9 month follow-up
Macrophage arc were measured on OCT images with NA every 0.2-mm intervals and divided 4 groups as follows: grade 0, no mac¬rophage; grade 1, localized macrophage accumulation (\<30°); grade 2, clus¬tered accumulation ≥30° and \<90°; grade 3, clus¬tered accumulation ≥90° and \<270°; and grade 4, clustered accumulation ≥270° and \<360° . Macrophage grade was evaluated as summation of 0 to 4 grades across all cross section in NA.
Time frame: Baseline and 9 month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.